EcoDrugPlus

40s Ribosomal Protein S5-Like

Ensembl ID : ENSNBRG00000018402
Gene Symbol: LOC102782526
3 Cross references
263 Possible Orthologues:

40s Ribosomal Protein S8-Like

Ensembl ID : ENSNBRG00000015531
Gene Symbol: LOC102789894
3 Cross references
325 Possible Orthologues:

40s Ribosomal Protein S9-Like

Ensembl ID : ENSNBRG00000003450
Gene Symbol: LOC102788472
3 Cross references
235 Possible Orthologues:

40s Ribosomal Protein Sa-Like

Ensembl ID : ENSNBRG00000010854
Gene Symbol: LOC102777132
4 Cross references
515 Possible Orthologues:

5'-Nucleotidase Ecto

Ensembl ID : ENSNBRG00000006409
Gene Symbol: NT5E
4 Cross references
215 Possible Orthologues:

5'-Nucleotidase-Like

Ensembl ID : ENSNBRG00000012327
Gene Symbol: LOC102782906
4 Cross references
180 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 1a B

Ensembl ID : ENSNBRG00000021526
Gene Symbol: HTR1AB
1 Cross references
137 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 2c, G Protein-Coupled-Like 1

Ensembl ID : ENSNBRG00000017742
Gene Symbol: HTR2CL1
1 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSNBRG00000006610
Gene Symbol: HTR1B
4 Cross references
182 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSNBRG00000011065
Gene Symbol: HTR1B
2 Cross references
181 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f-Like

Ensembl ID : ENSNBRG00000003114
Gene Symbol: LOC102787004
2 Cross references
66 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSNBRG00000014598
Gene Symbol: HTR2A
1 Cross references
216 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).